336 related articles for article (PubMed ID: 31741282)
1. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
Schreiber J; Schwab Sauerbeck I; Mailänder C
Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
[TBL] [Abstract][Full Text] [Related]
2. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
3. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
[TBL] [Abstract][Full Text] [Related]
4. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
6. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
[TBL] [Abstract][Full Text] [Related]
7. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma.
Pereira Barbosa M; Bugalho de Almeida A; Pereira C; Chen CW; Georgiou P; Peachey G;
Rev Port Pneumol (2006); 2015; 21(3):151-6. PubMed ID: 25926246
[TBL] [Abstract][Full Text] [Related]
8. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
10. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
12. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
[TBL] [Abstract][Full Text] [Related]
13. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
[TBL] [Abstract][Full Text] [Related]
14. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
15. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
16. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.
Colombo GL; Di Matteo S; Martinotti C; Oselin M; Valentino MC; Bruno GM; Pitotti C; Menzella F
Ther Adv Respir Dis; 2019; 13():1753466619841350. PubMed ID: 31035904
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in patients with severe asthma: the XCLUSIVE study.
Schumann C; Kropf C; Wibmer T; Rüdiger S; Stoiber KM; Thielen A; Rottbauer W; Kroegel C
Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
[TBL] [Abstract][Full Text] [Related]
19. Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
Apsangikar P; Ghadge P; Naik M; Nair S
J Assoc Physicians India; 2020 Dec; 68(12):61-65. PubMed ID: 33247645
[TBL] [Abstract][Full Text] [Related]
20. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
